Georgina B. F. Hall, Rachael Birkbeck, Benjamin M. Brainard, Fernanda Camacho, Elizabeth B. Davidow, Dana N. LeVine, Andrew Mackin, Taylor Moss, Katherine J. Nash, Giacomo Stanzani, Daria Starybrat, David Q. Stoye, Carolyn Tai, John Thomason, Julie M. Walker, K. Jane Wardrop, Helen Wilson, Virginie A. Wurlod, Karen Humm
{"title":"一项评估狗急性输血反应发生率和风险因素的前瞻性多中心观察研究。","authors":"Georgina B. F. Hall, Rachael Birkbeck, Benjamin M. Brainard, Fernanda Camacho, Elizabeth B. Davidow, Dana N. LeVine, Andrew Mackin, Taylor Moss, Katherine J. Nash, Giacomo Stanzani, Daria Starybrat, David Q. Stoye, Carolyn Tai, John Thomason, Julie M. Walker, K. Jane Wardrop, Helen Wilson, Virginie A. Wurlod, Karen Humm","doi":"10.1111/jvim.17175","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Reported incidence of blood transfusion reactions (TR) varies greatly.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To prospectively evaluate the incidence of acute TRs in dogs receiving allogenic blood products, using consensus definitions, and to assess factors associated with TRs.</p>\n </section>\n \n <section>\n \n <h3> Animals</h3>\n \n <p>Dogs (n = 858) administered allogenic blood products (n = 1542) between March and November 2022.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Prospective, multicenter surveillance study occurring in referral hospitals in the United States, United Kingdom, and Australia recording TRs in dogs administered blood products as defined by the consensus guidelines published by The Association of Veterinary Hematology and Transfusion Medicine in 2021.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The incidence of acute TR was 8.9% (95% CI 7.0-11.1) for packed red blood cells (pRBCs) and 4.5% (95% CI 2.9-6.6) for plasma products. The most frequently reported TRs were febrile nonhemolytic TRs (FNHTR; 4%, 95% CI 2.8-5.5) when administering pRBCs and allergic TRs (3.2%, 95% CI 1.80-5.10) when administering plasma products. A higher dose of pRBC (adjusted odds ratio [aOR] 1.04 [95% CI 1.00-1.08]) was associated with a higher odds of TR. Administration of pRBCs stored for longer than 28 days was associated with higher odds of FNHTR (aOR 4.10 [95% CI 1.58-10.65]) and acute hemolytic TR (AHTR; OR 15.2 [95% CI 3.35-68.70]) when compared with pRBCs stored for 14 days or fewer. Leukoreduction of pRBC was not associated with lower odds of developing a TR (OR 1.47 [95% CI 0.89-2.42]).</p>\n </section>\n \n <section>\n \n <h3> Conclusions and Clinical Importance</h3>\n \n <p>Clinicians should be mindful of the age and dose of pRBC prescribed to dogs.</p>\n </section>\n </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"38 5","pages":"2495-2506"},"PeriodicalIF":2.1000,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.17175","citationCount":"0","resultStr":"{\"title\":\"A prospective multicenter observational study assessing incidence and risk factors for acute blood transfusion reactions in dogs\",\"authors\":\"Georgina B. F. Hall, Rachael Birkbeck, Benjamin M. Brainard, Fernanda Camacho, Elizabeth B. Davidow, Dana N. LeVine, Andrew Mackin, Taylor Moss, Katherine J. Nash, Giacomo Stanzani, Daria Starybrat, David Q. Stoye, Carolyn Tai, John Thomason, Julie M. Walker, K. Jane Wardrop, Helen Wilson, Virginie A. Wurlod, Karen Humm\",\"doi\":\"10.1111/jvim.17175\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Reported incidence of blood transfusion reactions (TR) varies greatly.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To prospectively evaluate the incidence of acute TRs in dogs receiving allogenic blood products, using consensus definitions, and to assess factors associated with TRs.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Animals</h3>\\n \\n <p>Dogs (n = 858) administered allogenic blood products (n = 1542) between March and November 2022.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Prospective, multicenter surveillance study occurring in referral hospitals in the United States, United Kingdom, and Australia recording TRs in dogs administered blood products as defined by the consensus guidelines published by The Association of Veterinary Hematology and Transfusion Medicine in 2021.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The incidence of acute TR was 8.9% (95% CI 7.0-11.1) for packed red blood cells (pRBCs) and 4.5% (95% CI 2.9-6.6) for plasma products. The most frequently reported TRs were febrile nonhemolytic TRs (FNHTR; 4%, 95% CI 2.8-5.5) when administering pRBCs and allergic TRs (3.2%, 95% CI 1.80-5.10) when administering plasma products. A higher dose of pRBC (adjusted odds ratio [aOR] 1.04 [95% CI 1.00-1.08]) was associated with a higher odds of TR. Administration of pRBCs stored for longer than 28 days was associated with higher odds of FNHTR (aOR 4.10 [95% CI 1.58-10.65]) and acute hemolytic TR (AHTR; OR 15.2 [95% CI 3.35-68.70]) when compared with pRBCs stored for 14 days or fewer. Leukoreduction of pRBC was not associated with lower odds of developing a TR (OR 1.47 [95% CI 0.89-2.42]).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions and Clinical Importance</h3>\\n \\n <p>Clinicians should be mindful of the age and dose of pRBC prescribed to dogs.</p>\\n </section>\\n </div>\",\"PeriodicalId\":49958,\"journal\":{\"name\":\"Journal of Veterinary Internal Medicine\",\"volume\":\"38 5\",\"pages\":\"2495-2506\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-09-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.17175\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Veterinary Internal Medicine\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jvim.17175\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Internal Medicine","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvim.17175","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景：据报道，输血反应（TR）的发生率差异很大：报告的输血反应（TR）发生率差异很大：采用共识定义，前瞻性评估接受异体血制品的犬急性输血反应的发生率，并评估与输血反应相关的因素：动物：2022 年 3 月至 11 月期间接受异体血制品治疗的犬（n = 858）（n = 1542）：方法：在美国、英国和澳大利亚的转诊医院开展前瞻性多中心监测研究，记录根据兽医血液学和输血医学协会于2021年发布的共识指南所定义的狗血液制品TR：包装红细胞（pRBCs）和血浆产品的急性TR发生率分别为8.9%（95% CI 7.0-11.1）和4.5%（95% CI 2.9-6.6）。在使用 pRBC 时，最常报告的 TR 是发热性非溶血性 TR（FNHTR；4%，95% CI 2.8-5.5），而在使用血浆产品时，最常报告的 TR 是过敏性 TR（3.2%，95% CI 1.80-5.10）。pRBC 剂量越大（调整后的几率比 [aOR] 1.04 [95% CI 1.00-1.08]），发生 TR 的几率越高。与储存 14 天或更短时间的 pRBC 相比，储存超过 28 天的 pRBC 与更高的 FNHTR（aOR 4.10 [95% CI 1.58-10.65]）和急性溶血 TR（AHTR；OR 15.2 [95% CI 3.35-68.70]）几率相关。pRBC 的白细胞减少与发生 TR 的几率降低无关（OR 1.47 [95% CI 0.89-2.42]）：结论和临床意义：临床医生应注意给狗注射 pRBC 的年龄和剂量。
A prospective multicenter observational study assessing incidence and risk factors for acute blood transfusion reactions in dogs
Background
Reported incidence of blood transfusion reactions (TR) varies greatly.
Objective
To prospectively evaluate the incidence of acute TRs in dogs receiving allogenic blood products, using consensus definitions, and to assess factors associated with TRs.
Animals
Dogs (n = 858) administered allogenic blood products (n = 1542) between March and November 2022.
Methods
Prospective, multicenter surveillance study occurring in referral hospitals in the United States, United Kingdom, and Australia recording TRs in dogs administered blood products as defined by the consensus guidelines published by The Association of Veterinary Hematology and Transfusion Medicine in 2021.
Results
The incidence of acute TR was 8.9% (95% CI 7.0-11.1) for packed red blood cells (pRBCs) and 4.5% (95% CI 2.9-6.6) for plasma products. The most frequently reported TRs were febrile nonhemolytic TRs (FNHTR; 4%, 95% CI 2.8-5.5) when administering pRBCs and allergic TRs (3.2%, 95% CI 1.80-5.10) when administering plasma products. A higher dose of pRBC (adjusted odds ratio [aOR] 1.04 [95% CI 1.00-1.08]) was associated with a higher odds of TR. Administration of pRBCs stored for longer than 28 days was associated with higher odds of FNHTR (aOR 4.10 [95% CI 1.58-10.65]) and acute hemolytic TR (AHTR; OR 15.2 [95% CI 3.35-68.70]) when compared with pRBCs stored for 14 days or fewer. Leukoreduction of pRBC was not associated with lower odds of developing a TR (OR 1.47 [95% CI 0.89-2.42]).
Conclusions and Clinical Importance
Clinicians should be mindful of the age and dose of pRBC prescribed to dogs.
期刊介绍：
The mission of the Journal of Veterinary Internal Medicine is to advance veterinary medical knowledge and improve the lives of animals by publication of authoritative scientific articles of animal diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
